Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …

Multi‐agent induction chemotherapy (IC) improves response rates in younger patients with
acute myeloid leukemia (AML); however, relapse remains the principal cause of treatment …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Acute myeloid leukemia (AML) is a hematologic malignancy that most frequently develops in
older adults. Overall, AML is associated with a high mortality although advancements in …

Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …

Living cell‐based drug delivery systems (LC‐DDSs) are limited by adverse interactions
between drugs and carrier cells, typically drug‐induced toxicity to carrier cells and restriction …

Accurate classification and risk stratification are critical for clinical decision making in
patients with acute myeloid leukemia (AML). In the newly proposed World Health …